Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation
Mariah L. Wright(Nationwide Children's Hospital), Rajinder Bajwa(Nationwide Children's Hospital), Kimberly Taylor(Nationwide Children's Hospital), Dean A. Lee(Nationwide Children's Hospital), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Jeffery J. Auletta(Nationwide Children's Hospital), Rolla Abu‐Arja(Nationwide Children's Hospital), Vinita B. Pai(Nationwide Children's Hospital), Veronika Polishchuk(Albert Einstein College of Medicine)
Cited by 4
Related Papers
Identification of Biomarkers for Differentiation of Hypervirulent Klebsiella pneumoniae from Classical K. pneumoniae
|Journal of Clinical Microbiology|2018|775
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
|Blood|2016|333
COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients
|Journal of Infection|2021|248
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237